Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Matrix metalloproteinases as biomarkers and treatment targets in mesothelioma : a systematic review
ID
Štrbac, Danijela
(
Author
),
ID
Dolžan, Vita
(
Author
)
PDF - Presentation file,
Download
(380,41 KB)
MD5: 1CFB9E494B42D5760F81FD2169CCF7A0
URL - Source URL, Visit
https://www.mdpi.com/2218-273X/11/9/1272
Image galllery
Abstract
Metalloproteinases (MMPs) have an important role in tissue remodeling and have been shown to have an effect on tumor progression, invasion, metastasis formation, and apoptosis in several tumors, including mesothelioma. Mesothelioma is a rare tumor arising from pleura and peritoneum and is frequently associated with asbestos exposure. We have performed a systematic search of PubMed.gov and ClinicalTrials.gov databases to retrieve and review three groups of studies: studies of MMPs expression in tumor tissue or body fluids in patients with mesothelioma, studies of MMPs genetic variability, and studies of MMPs as potential novel drug targets in mesothelioma. Several studies of MMPs in mesothelioma tissues reported a link between higher expression levels of commonly studied MMPs and clinical parameters, such as overall survival. Fewer studies have investigated genetic variability of MMP genes. Nevertheless, these studies suggested that certain genetic variants in MMP genes can have either protective or tumor-promoting effects on mesothelioma patients. MMPs have been also reported as novel drug targets, but so far no clinical trials of MMP inhibitors are registered in mesothelioma. In conclusion, MMPs play an important role in mesothelioma, but further studies are needed to elucidate the potentials of MMPs as biomarkers and drug targets in mesothelioma.
Language:
English
Keywords:
mesothelioma
,
metalloproteinases
,
genetic variability
,
biomarker
,
drug target
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2021
Number of pages:
10 str.
Numbering:
Vol. 11, iss. 9, art. 1272
PID:
20.500.12556/RUL-136046
UDC:
616-006
ISSN on article:
2218-273X
DOI:
10.3390/biom11091272
COBISS.SI-ID:
74658819
Publication date in RUL:
08.04.2022
Views:
1065
Downloads:
130
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Biomolecules
Shortened title:
Biomolecules
Publisher:
MDPI
ISSN:
2218-273X
COBISS.SI-ID:
519952921
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
01.09.2021
Secondary language
Language:
Slovenian
Keywords:
mezoteliom
,
metaloproteinaza
,
genetska variabilnost
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0170
Name:
Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku
Funder:
ARRS - Slovenian Research Agency
Project number:
L3-8203
Name:
Serumski, genetski in epigenetski označevalci tveganja za nastanek, napredovanja in odgovora na zdravljenje bolezni, povezanih z izpostavljenostjo azbestu
Funder:
ARRS - Slovenian Research Agency
Project number:
L3-2622
Name:
Biološki označevalci nastanka, napredovanja in odgovora na zdravljenje bolezni, povezanih z izpostavljenostjo azbestu
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back